UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

Journal of clinical oncology, 2018-05, Vol.36 (14), p.1412-1418

2018

Volltextzugriff (PDF)

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Clinical cancer research, 2018-06, Vol.24 (12), p.2771-2779

2018

Volltextzugriff (PDF)

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

Cancer discovery, 2016-06, Vol.6 (6), p.601-611

2016

Volltextzugriff (PDF)

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

Lung cancer (Amsterdam, Netherlands), 2017-04, Vol.106, p.110-114

2017

Volltextzugriff (PDF)

Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs

Nature communications, 2017-11, Vol.8 (1), p.1801-19, Article 1801

2017

Volltextzugriff (PDF)

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR )-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

Frontiers in oncology, 2019-03, Vol.9, p.132-132

2019

Volltextzugriff (PDF)

Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC

JTO clinical and research reports, 2021-10, Vol.2 (10), p.100221-100221, Article 100221

2021

Volltextzugriff (PDF)

Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice

JTO clinical and research reports, 2022-05, Vol.3 (5), p.100310, Article 100310

2022

Volltextzugriff (PDF)

The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer

JTO clinical and research reports, 2021-07, Vol.2 (7), p.100194-100194, Article 100194

2021

Volltextzugriff (PDF)

Epigenetic therapy in lung cancer

Frontiers in oncology, 2013-01, Vol.3, p.135

2013

Volltextzugriff (PDF)

Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non–small cell lung cancer in the randomized phase III IMpower010 trial

The Journal of thoracic and cardiovascular surgery, 2023-09, Vol.166 (3), p.655-666.e7

2023

Volltextzugriff (PDF)

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib

Journal of thoracic oncology, 2017-03, Vol.12 (3), p.446-457

2017

Volltextzugriff (PDF)

COLLECTING DUCT RENAL CELL CARCINOMA: CLINICAL STUDY OF A RARE TUMOR

The Journal of urology, 2002, Vol.167 (1), p.71-74

2002

Volltextzugriff (PDF)

Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma

Oncotarget, 2024-07, Vol.15 (1), p.444-458

2024

Volltextzugriff (PDF)

Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

Clinical cancer research, 2012-02, Vol.18 (4), p.1092-1100

2012

Volltextzugriff (PDF)

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8500-8500

2021

Volltextzugriff (PDF)

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2014-04, Vol.9 (4), p.577-582

2014

Volltextzugriff (PDF)

Eribulin: a new-generation antimicrotubule agent in lung cancer therapy

Future oncology (London, England), 2014-10, Vol.10 (12), p.1913-1924

2014

Volltextzugriff (PDF)

Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

Lung cancer (Amsterdam, Netherlands), 2012-10, Vol.78 (1), p.76-80

2012

Volltextzugriff (PDF)

Renal Cell Carcinoma With Retroperitoneal Lymph Nodes: Role of Lymph Node Dissection

The Journal of urology, 2003-06, Vol.169 (6), p.2076-2083

2003

Volltextzugriff (PDF)

A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2018-10, Vol.82 (4), p.723-732

2018

Volltextzugriff (PDF)

Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of Southwest Oncology Group Trials

Journal of thoracic oncology, 2015-01, Vol.10 (1), p.110-115

2015

Volltextzugriff (PDF)

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial

Journal of thoracic oncology, 2010-11, Vol.5 (11), p.1835-1840

2010

Volltextzugriff (PDF)

Cytokine-based therapy for metastatic renal cell cancer

Urologic Clinics of North America, 2003-08, Vol.30 (3), p.589-600

2003

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(72)

Sprache

Englisch
(72)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR )-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC

Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs

Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice

The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer

Epigenetic therapy in lung cancer

Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non–small cell lung cancer in the randomized phase III IMpower010 trial

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib

COLLECTING DUCT RENAL CELL CARCINOMA: CLINICAL STUDY OF A RARE TUMOR

Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma

Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC)

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non–Small-Cell Lung Cancer

Eribulin: a new-generation antimicrotubule agent in lung cancer therapy

Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

Renal Cell Carcinoma With Retroperitoneal Lymph Nodes: Role of Lymph Node Dissection

A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors

Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of Southwest Oncology Group Trials

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial

Cytokine-based therapy for metastatic renal cell cancer

Suchergebnisse filtern